시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 비알코올성 지방성 간염(NASH) 시장 보고서(2025년)
Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2025
상품코드 : 1678162
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,371,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,209,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,048,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

비알코올성 지방성 간염(NASH) 시장 규모는 향후 수년간 비약적인 성장이 전망됩니다. 2029년에는 CAGR 32.8%로 190억 7,000만 달러로 성장합니다. 예측 기간 중의 성장은 NASH 치료제 개발의 진전, NASH 스크리닝 구상 증가, 의료비 상승, 공동 연구 노력, 정부 지원, 규제 등에 기인하는 것으로 추정됩니다. 예측 기간의 주요 동향으로는 생활습관 중재 및 환자 교육에 대한 집중, 임상연구의 공동연구 증가, 규제 발전 및 경로 지정, 진단 및 모니터링에 인공지능의 통합 등이 있습니다.

비만 유병률 증가는 비알코올성 지방간염(NASH) 시장 수요를 주도하고 있습니다. 비만은 건강에 심각한 위험을 초래하는 비정상적이거나 과도한 지방의 축적, 그리고 특정 신장의 사람들에게 건강하다고 여겨지는 체중을 초과하는 것을 특징으로 합니다. 비만과 관련된 비알코올성 지방간 질환의 유병률이 증가함에 따라 NASH는 향후 수십년간 심각한 간 질환의 주요 원인 중 하나가 될 것으로 예상되며, NASH 치료제 및 관련 약품에 대한 수요가 증가하고 있습니다. 예를 들어 2024년 3월 영국에 본부를 둔 국제 공중보건기구인 세계보건기구(WHO)는 2022년 18세 이상 성인 중 약 25억 명이 과체중으로 분류될 것이며, 그 중 8억 9천만 명이 비만과 함께 생활하고 있다고 보고했습니다. 이처럼 비만 환자 증가는 비알코올성 지방간염(NASH) 시장의 성장을 가속할 것으로 예상됩니다.

노인 인구 증가는 비알코올성 지방간염(NASH) 시장 수요를 촉진하는 주요 요인입니다. 노인 인구는 65세 이상의 노인을 의미하며, 노화에 따른 독특한 헬스케어 요구를 나타내며, NASH 시장의 지속적인 치료법 개발과 발전은 노인의 전반적인 건강 상태를 개선하고 노인에게 만연한 간 관련 질병을 해결하는 데 중요한 역할을 합니다. 세계보건기구(WHO)가 2022년 10월에 발표한 바와 같이, 전 세계 노인 인구가 크게 증가하여 2030년에는 6명 중 1명이 60세 이상, 2050년에는 21억 명의 노인이 태어날 것으로 예상됩니다. 이러한 인구 통계학적 변화는 비알코올성 지방간염(NASH) 시장의 성장을 가속하는 데 있으며, 노인 인구 증가가 필수적인 역할을 할 것임을 강조하고 있습니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, Covid, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

Non-alcoholic steatohepatitis (NASH) represents an advanced stage of fatty liver disease, distinguished by inflammation of the liver, and has the potential to progress to cirrhosis and liver failure.

Non-alcoholic steatohepatitis (NASH) is classified into solid and liquid forms. Solid variants are predominantly produced in crystalline forms, sold in tablet formats for oral consumption, owing to their superior purity and durability. Products in this category, such as vitamin E, pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, and others, target various health conditions including hypertension, heart disease, high blood lipid, type 2 diabetes, and obesity. These products are distributed through hospital pharmacies, retail pharmacies, and online providers, encompassing both oral and parenteral applications.

The non-alcoholic steatohepatitis (NASH) market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis (NASH) market statistics, including non-alcoholic steatohepatitis (NASH) industry global market size, regional shares, competitors with non-alcoholic steatohepatitis (NASH) market share, detailed non-alcoholic steatohepatitis (NASH) market segments, market trends, and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis (NASH) industry. This non-alcoholic steatohepatitis (NASH) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The non-alcoholic steatohepatitis (NASH) market size has grown exponentially in recent years. It will grow from $4.5 billion in 2024 to $6.13 billion in 2025 at a compound annual growth rate (CAGR) of 36.1%. The growth in the historic period can be attributed to rising prevalence of NASH, obesity epidemic, growing awareness and diagnoses, shift in lifestyle and dietary patterns, healthcare infrastructure development.

The non-alcoholic steatohepatitis (NASH) market size is expected to see exponential growth in the next few years. It will grow to $19.07 billion in 2029 at a compound annual growth rate (CAGR) of 32.8%. The growth in the forecast period can be attributed to advancements in NASH drug development, increasing NASH screening initiatives, rising healthcare expenditure, collaborative research efforts, government support and regulations. Major trends in the forecast period include focus on lifestyle interventions and patient education, increased collaboration in clinical research, regulatory advancements and pathway designations, integration of artificial intelligence in diagnosis and monitoring.

The increasing prevalence of obesity is driving the demand for the non-alcoholic steatohepatitis (NASH) market. Obesity is characterized by an abnormal or excessive accumulation of fat that poses significant health risks, as well as a body weight exceeding what is considered healthy for a person of a specific height. With the growing incidence of non-alcoholic fatty liver disease linked to the obesity epidemic, NASH is projected to become one of the leading causes of severe liver disease in the coming decades, heightening the demand for NASH treatments and related medications. For example, in March 2024, the World Health Organization (WHO), a UK-based international public health organization, reported that in 2022, approximately 2.5 billion adults aged 18 and older were classified as overweight, with 890 million of them living with obesity. Thus, the rise in obesity cases is expected to drive the growth of the non-alcoholic steatohepatitis (NASH) market.

The rising demographic of the geriatric population is a key driver fueling the demand for the non-alcoholic steatohepatitis (NASH) market. The geriatric population, representing individuals aged 65 and older, exhibits specific healthcare needs associated with aging. The ongoing development and advancements in treatments within the NASH market play a crucial role in enhancing overall health outcomes for the elderly, addressing a prevalent liver-related condition prevalent in aging individuals. As indicated by the World Health Organization in October 2022, the global elderly population is anticipated to witness a significant increase, with 1 in 6 individuals being 60 or older by 2030 and an estimated 2.1 billion elderly people by 2050. This demographic shift underscores the imperative role of the increasing geriatric population in driving the growth of the Non-Alcoholic Steatohepatitis (NASH) market.

Major companies in the non-alcoholic steatohepatitis (NASH) market are focusing on the development of thyroid hormone receptor-beta (THR-beta) agonists to improve liver metabolism, decrease liver fat accumulation, and enhance liver function. THR-beta agonists are compounds that specifically activate the thyroid hormone receptor-beta subtype, a crucial receptor involved in regulating metabolism, growth, and development. For instance, in March 2024, the U.S. Food and Drug Administration (FDA) approved Rezdiffra (resmetirom), the first treatment for adults with noncirrhotic NASH and moderate to advanced liver scarring (fibrosis). By selectively activating the THR-beta receptor, Rezdiffra aids in regulating lipid metabolism, resulting in a reduction of intrahepatic triglycerides and overall liver fat accumulation.

Prominent companies in the non-alcoholic steatohepatitis (NASH) market are actively engaged in the development of innovative products, exemplified by a focus on a thyroid hormone receptor (THR)-B selective agonist. This innovative therapeutic approach is designed to target fundamental underlying causes of non-alcoholic steatohepatitis. The thyroid hormone receptor, a pivotal protein regulating gene expression upon binding with thyroid hormones, plays a crucial role in various physiological processes. A case in point is Madrigal Pharmaceuticals, Inc., a US-based clinical-stage biopharmaceutical company, which completed the submission of a New Drug Application in July 2023, seeking accelerated approval for Resmetirom in the treatment of NASH with liver fibrosis. Resmetirom, offering once-daily oral therapy and liver-directed action, specifically targets hepatic steatosis, inflammation, and hepatocellular injury associated with NASH and liver fibrosis. Notably designated as a Breakthrough Therapy by the FDA, and supported by a comprehensive clinical development program, including Phase 3 trials, Resmetirom showcases significant potential to address unmet medical needs. This advancement positions it as a promising addition to the evolving treatment landscape for NASH with liver fibrosis.

In July 2022, Advanz Pharma Corp. Limited, a prominent UK-based pharmaceutical company, successfully acquired Intercept Pharmaceuticals Inc for an undisclosed sum. This strategic acquisition is designed to solidify Advanz Pharma's position in the rare disease treatment sector, specifically through the addition of the ex-U.S. rights to Ocaliva (obeticholic acid), an orphan medicine used for treating primary biliary cholangitis (PBC). Intercept Pharmaceuticals Inc., a distinguished U.S.-based biopharmaceutical company specializing in innovative therapies for progressive non-viral liver disorders, aligns well with Advanz Pharma's strategic goals in expanding its pharmaceutical portfolio.

Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-alcoholic steatohepatitis (nash) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-alcoholic steatohepatitis (NASH) market consists of sales of drugs that are used for the treatment of non-alcoholic fatty liver diseases. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-alcoholic steatohepatitis (nash) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for non-alcoholic steatohepatitis (nash) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-alcoholic steatohepatitis (nash) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Non-Alcoholic Steatohepatitis (NASH) Market Characteristics

3. Non-Alcoholic Steatohepatitis (NASH) Market Trends And Strategies

4. Non-Alcoholic Steatohepatitis (NASH) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Non-Alcoholic Steatohepatitis (NASH) Growth Analysis And Strategic Analysis Framework

6. Non-Alcoholic Steatohepatitis (NASH) Market Segmentation

7. Non-Alcoholic Steatohepatitis (NASH) Market Regional And Country Analysis

8. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market

9. China Non-Alcoholic Steatohepatitis (NASH) Market

10. India Non-Alcoholic Steatohepatitis (NASH) Market

11. Japan Non-Alcoholic Steatohepatitis (NASH) Market

12. Australia Non-Alcoholic Steatohepatitis (NASH) Market

13. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market

14. South Korea Non-Alcoholic Steatohepatitis (NASH) Market

15. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market

16. UK Non-Alcoholic Steatohepatitis (NASH) Market

17. Germany Non-Alcoholic Steatohepatitis (NASH) Market

18. France Non-Alcoholic Steatohepatitis (NASH) Market

19. Italy Non-Alcoholic Steatohepatitis (NASH) Market

20. Spain Non-Alcoholic Steatohepatitis (NASH) Market

21. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market

22. Russia Non-Alcoholic Steatohepatitis (NASH) Market

23. North America Non-Alcoholic Steatohepatitis (NASH) Market

24. USA Non-Alcoholic Steatohepatitis (NASH) Market

25. Canada Non-Alcoholic Steatohepatitis (NASH) Market

26. South America Non-Alcoholic Steatohepatitis (NASH) Market

27. Brazil Non-Alcoholic Steatohepatitis (NASH) Market

28. Middle East Non-Alcoholic Steatohepatitis (NASH) Market

29. Africa Non-Alcoholic Steatohepatitis (NASH) Market

30. Non-Alcoholic Steatohepatitis (NASH) Market Competitive Landscape And Company Profiles

31. Non-Alcoholic Steatohepatitis (NASH) Market Other Major And Innovative Companies

32. Global Non-Alcoholic Steatohepatitis (NASH) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis (NASH) Market

34. Recent Developments In The Non-Alcoholic Steatohepatitis (NASH) Market

35. Non-Alcoholic Steatohepatitis (NASH) Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기